A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA First published 28/03/2019 Last updated 02/07/2024 EU PAS number:EUPAS28992 Study Finalised